Nebivolol Dosing for Hypertension and Heart Failure
For hypertension, start nebivolol at 5 mg once daily and titrate up to 40 mg daily as needed; for heart failure, start at 1.25 mg once daily and titrate to a target of 10 mg once daily. 1
Standard Dosing for Hypertension
The FDA-approved dosing for hypertension begins at 5 mg once daily (with or without food), either as monotherapy or combined with other agents 1. For patients requiring additional blood pressure reduction:
- Titrate at 2-week intervals up to a maximum of 40 mg once daily
- More frequent dosing provides no additional benefit 1
- The 2017 ACC/AHA guidelines list nebivolol at 5-40 mg once daily as a cardioselective beta-blocker with vasodilatory properties 2
Heart Failure Dosing
For heart failure with reduced ejection fraction, nebivolol follows a different titration schedule 3, 4:
- Starting dose: 1.25 mg once daily under supervision in an outpatient setting
- Titration schedule: Double the dose every 2-4 weeks as tolerated
- Target dose: 10 mg once daily (evidence-based dose from clinical trials)
- Do not increase if signs of worsening heart failure, symptomatic hypotension, or excessive bradycardia (pulse <50/min) occur 3
The SENIORS trial established nebivolol's efficacy in elderly heart failure patients, demonstrating reduced morbidity and mortality when titrated to 10 mg daily 3, 4, 5.
Dose Adjustments for Special Populations
Severe Renal Impairment (CrCl <30 mL/min)
- Initial dose: 2.5 mg once daily
- Titrate slowly as needed 1
- Stage 3-4 CKD increases nebivolol exposure 3-fold, but hemodialysis restores pharmacokinetics to normal 6
- Not studied in dialysis patients 1
Moderate Hepatic Impairment
- Initial dose: 2.5 mg once daily
- Titrate slowly as needed 1
- Moderate hepatic impairment increases d-nebivolol peak concentration 3-fold and AUC 10-fold 1
- Contraindicated in severe hepatic impairment 1
CYP2D6 Poor Metabolizers
No dose adjustment necessary despite significantly altered pharmacokinetics 1. This is a critical clinical point: poor metabolizers have 5-fold higher Cmax and 10-fold higher AUC of d-nebivolol compared to extensive metabolizers 1, 7, yet clinical efficacy and safety profiles remain similar 1, 8. The active hydroxyl metabolites and glucuronides contribute substantially to beta-blocking activity, compensating for the pharmacokinetic differences 1.
Elderly Patients
No dose adjustment required 1. The SENIORS trial specifically demonstrated equivalent tolerance and benefits in patients ≥70 years with heart failure 3.
Clinical Considerations
Nebivolol is among the evidence-based beta-blockers recommended for heart failure alongside carvedilol, metoprolol succinate, and bisoprolol 9, 4, 10. Its unique nitric oxide-mediated vasodilation distinguishes it from other beta-blockers 2, 5.
Key Monitoring Parameters
- Blood pressure and heart rate at each titration
- Signs of worsening heart failure (fluid retention, dyspnea)
- Symptomatic hypotension or bradycardia 3
Common Pitfalls to Avoid
- Do not discontinue abruptly in patients with ischemic heart disease 2
- Do not withhold for mild hypotension if asymptomatic—the benefits of target dosing outweigh concerns about modest blood pressure reductions 10
- Do not avoid in CYP2D6 poor metabolizers—they achieve similar clinical outcomes despite altered pharmacokinetics 1, 8
- Do not use more frequent than once-daily dosing for hypertension—it provides no additional benefit 1
The evidence strongly supports aggressive uptitration to target doses when tolerated, as higher doses correlate with improved cardiovascular outcomes in heart failure populations 3, 4.